Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05952037 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
A Phase 2 study of Waldenstrom Macroglobulinemia and Waldenstrom's Macroglobulinemia Recurrent, sponsored by BeOne Medicines.
- Active
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
- 20
- Study locations
NCT05952037 is a Phase 2 study of Waldenstrom Macroglobulinemia and Waldenstrom's Macroglobulinemia Recurrent that is active but no longer recruiting, run by BeOne Medicines. The registered enrollment target is 114 participants, below the 470-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 19 states.
The verdict
NCT05952037, a Phase 2 study of Waldenstrom Macroglobulinemia and Waldenstrom's Macroglobulinemia Recurrent, is active but no longer recruiting, sponsored by BeOne Medicines.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
Conditions Studied
Interventions
- DRUG Zanubrutinib
- DRUG Sonrotoclax
Study Locations (20)
New South Wales
- Concord Repatriation General Hospital - Concord
- Genesiscare North Shore - St Leonards
California
- City of Hope National Medical Center - Duarte
Colorado
- Colorado Blood Cancer Institute - Denver
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Florida
- University of Miami - Miami
Illinois
- Northwestern Medicine Cancer Center - Warrenville
Iowa
- Mission Cancer and Blood - Waukee
Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05952037
The ClinicalTrials.gov registry entry for NCT05952037 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 470-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (76% lower). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.
NCT05952037 reports 20 study locations spanning 19 distinct geographic areas - top geographies include New South Wales, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05952037 about?
NCT05952037 is a clinical study titled "A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia". This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
What is the current status of trial NCT05952037?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2023-10-23. Estimated completion is 2028-08.
What conditions does trial NCT05952037 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory.
What interventions are being tested in trial NCT05952037?
The interventions under investigation include: Zanubrutinib (DRUG), Sonrotoclax (DRUG).
Who is sponsoring clinical trial NCT05952037?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05952037 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Epcoritamab in Previously Treated WM
RECRUITING · Phase 2
-
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RECRUITING · Phase 2
-
Loncastuximab Tesirine in WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
Explore more on PlainTrial
Waldenstrom Macroglobulinemia
All registered trials for this condition
Waldenstrom's Macroglobulinemia Recurrent
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.